Marc Banjak
General Counsel bei DOVA PHARMACEUTICALS, INC.
Profil
Marc A.
Banjak is currently the Secretary & General Counsel at iBio, Inc. and the General Counsel at Dova Pharmaceuticals, Inc. He previously worked as the General Counsel at Istari Oncology, Inc. Banjak received his undergraduate degree from Franklin & Marshall College, his graduate degree from the University of Denver, and his doctorate from Sturm College of Law.
Aktive Positionen von Marc Banjak
| Unternehmen | Position | Beginn |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | General Counsel | - |
| IBIO, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Marc Banjak
| Unternehmen | Position | Ende |
|---|---|---|
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Comptroller/Controller/Auditor | - |
Ausbildung von Marc Banjak
| Franklin & Marshall College | Undergraduate Degree |
| University of Denver | Graduate Degree |
| Sturm College of Law | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IBIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
